ZIM.STU Zimmer Biomet Holdings Inc.
- Market cap
- -
- P/E
- 23.8x
- P/B
- 1.34x
- ROE
- 6.9%
- Dividend yield
- 0.81%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ZIM.STU undervalued?
Graham numberThe Graham number of Zimmer Biomet Holdings Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zimmer Biomet Holdings Inc. fundamental analysis
No fundamental analysis for Zimmer Biomet Holdings Inc. yet.
Zimmer Biomet Holdings Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zimmer Biomet Holdings Inc.
There is no Profile data available for ZIM.SG.
Full company profileZimmer Biomet Holdings Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zimmer Biomet Holdings Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.68B | 7.82B | 7.93B | 7.98B | 6.13B | 6.83B | 6.94B | 7.39B | 7.68B | 8.23B | 8.53B |
| Gross Profit | 5.30B | 5.69B | 5.66B | 5.73B | 4.30B | 4.87B | 4.92B | 5.31B | 5.49B | 5.74B | 6.10B |
| Operating Income | 1.09B | 1.35B | 1.15B | 1.27B | 705M | 1.01B | 1.19B | 1.45B | 1.53B | 1.36B | 1.54B |
| EBITDA | - | 1.85B | 1.06B | 2.14B | 970M | 1.65B | 1.49B | 2.22B | 2.25B | 2.22B | 2.48B |
| Net Income | 306M | 1.81B | -379M | 1.13B | -139M | 402M | 231M | 1.02B | 904M | 705M | 873M |
| EPS | - | 8.95 | -1.86 | 5.49 | -0.67 | 1.92 | 1.11 | 4.98 | 4.54 | 3.61 | 4.58 |
| Balance Sheet | |||||||||||
| Total Assets | 26.7B | 26.0B | 24.1B | 24.6B | 24.4B | 23.5B | 21.1B | 21.5B | 21.4B | 23.1B | 22.8B |
| Total Liabilities | 17.0B | 14.2B | 12.9B | 12.2B | 12.2B | 10.8B | 9.04B | 9.01B | 8.89B | 10.4B | 10.2B |
| Shareholders' Equity | 9.67B | 11.7B | 11.3B | 12.4B | 12.2B | 12.7B | 12.0B | 12.5B | 12.5B | 12.7B | 12.6B |
| Cash & Short-term Investments | 634M | 524M | 543M | 618M | 802M | 378M | 376M | 416M | 526M | 592M | 410M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.63B | 1.58B | 1.75B | 1.59B | 1.20B | 1.50B | 1.28B | 1.58B | 1.50B | 1.70B | 1.61B |
| Capital Expenditure | 530M | 493M | 163M | 405M | 112M | 144M | 188M | 395M | 357M | 277M | 383M |
| Free Cash Flow | - | 1.43B | 1.58B | 1.18B | 1.09B | 1.36B | 1.10B | 1.19B | 1.14B | 1.42B | 1.23B |
| Ratios | |||||||||||
| ROE | 3.2% | 15.5% | -3.4% | 9.1% | -1.1% | 3.2% | 1.9% | 8.2% | 7.2% | 5.6% | 6.9% |
| ROA | 1.1% | 7.0% | -1.6% | 4.6% | -0.6% | 1.7% | 1.1% | 4.8% | 4.2% | 3.1% | 3.8% |
| Net Profit Margin | 4.0% | 23.2% | -4.8% | 14.2% | -2.3% | 5.9% | 3.3% | 13.8% | 11.8% | 8.6% | 10.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Zimmer Biomet Holdings Inc. dividends
- Dividend yield
- 0.81%
- Forward dividend
- -
- Payout ratio
- 27.0%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 190M | 0.97 | 27.0% |
| 2024 | USD 196M | 0.98 | 21.7% |
| 2023 | USD 201M | 0.98 | 19.6% |
| 2022 | USD 201M | 0.96 | 86.9% |
| 2021 | USD 200M | 0.96 | 49.8% |
| 2020 | USD 199M | 0.96 | - |
| 2019 | USD 197M | 0.95 | 17.4% |
| 2018 | USD 195M | 0.96 | - |
| 2017 | EUR 194M | 0.96 | 10.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Zimmer Biomet Holdings Inc.
Ownership data of Zimmer Biomet Holdings Inc. is not available yet.
Zimmer Biomet Holdings Inc. company profile
- Company name
- Zimmer Biomet Holdings Inc.
- Ticker
- ZIM.STU
- Exchange
- Stuttgart Exchange
- Sector
- Other
- Industry
- Metals & Mining
- Fiscal year end
- December
- Address
- Website
- -
About Zimmer Biomet Holdings Inc.
There is no Profile data available for ZIM.SG.